The Lithuanian Ministry of Health and EFPIA have announced a new Joint Working Agreement.
The Lithuanian Ministry of Health and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have announced a new Joint Working Agreement that paves the way for protecting future health and growth in Lithuania.
The agreement is a concrete step towards delivering the vision of health and sustainable growth set out in the Vilnius Declaration, which was signed during Lithuania's Presidency of the EU last year, according to EFPIA. It sets out a series of measures to safeguard future innovation and healthcare, including establishing a specific ‘Reimbursement Budget’ that will reflect and be proportionate to both gross domestic product (GDP) growth and increase in overall public health care spending.
“We are creating a sustainable health care system that is prone to demographic and economic challenges, that promptly responds to current health threats, that incorporates newest technologies and best medical practices,” said Lithuanian Minister of Health Vytenis Povilas Andriukaitis. “The Ministry of Health and EFPIA working together means new treatment options for the patients, greater transparency for the healthcare industry and meaningful cooperation with innovative businesses.”
Through partnering on a holistic life sciences strategy, EFPIA and the Lithuanian Ministry of Health hope to make Lithuania a more attractive location for life sciences investment, and to support a healthy population through the creation of more effective, efficient and sustainable health systems.
According to EFPIA Director General Richard Bergström: “Our industry has entered into a number of agreements with European governments, but the Lithuanian agreement has achieved a new progressive, gold standard in collaboration for better health outcomes. It signifies a new dawn in our industry’s partnerships, as it delivers a much more comprehensive solution to meeting the health and economic needs of citizens. I urge other nations to learn from the Lithuanian approach.”
Such collaborative efforts are part of EFPIA’s recently launched strategy, “Health and Growth: Working together for a healthy Europe,” which advocates for an integrated life sciences sector for the EU.
Read the full announcement here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.